Table 5.

Results from the U-ACHIEVE trial with upadacitinib.

	Placebo [n = 46]	7.5 mg QD [n = 47]	15 mg QD [n = 49]	30 mg QD [n = 52]	45 mg QD [n = 56]
Clinical remission	0.0%	8.5%	14.3%*	13.5%*	19.6%**
Clinical response	13.0%	29.8%*	44.9%***	44.2%***	50.0%***
Endoscopic improvement	2.2%	14.9%*	30.6%***	26.9%***	35.7%***
Endoscopic remission	0.0%	6.4%	4.1%	9.6%*	17.9%**
Histological improvement	6.5%	31.9%**	51.0%***	44.2%***	48.2%***
Histological remission	2.2%	12.8%*	22.4%**	30.8%***	41.1%***

Clinical remission: clinical remission per adapted Mayo score at Week 8 [stool frequency sub-score ≤1, rectal bleeding sub-score = 0, and endoscopic sub-score ≤1]. Clinical response: clinical response per adapted Mayo score at Week 8 [decrease from baseline in the adapted Mayo score ≥2 points and ≥30% from baseline, plus a decrease in rectal bleeding score ≥1 or an absolute rectal bleeding score ≤1]. Endoscopic improvement: endoscopic sub-score ≤1. Endoscopic remission: endoscopic sub-score = 0. Histological improvement: any decrease from baseline in the Geboes score. Histological remission: a Geboes score <2.

QD: once daily.

*p <0.05; **p <0.01; ***p <0.001.